CJC-1295 Ipamorelin: Frequently Asked Questions

CJC-1295 is a synthetic GHRH analog studied for sustained GH release via albumin-bound half-life extension. Ipamorelin is a selective GHRP — a five-residue synthetic peptide that binds GHS-R1a for pulsatile GH secretion with minimal cortisol, prolactin, or gonadotropin side effects in published rat and swine studies.^[3] Combined, they operate on two distinct receptor arms of the GH axis.

The CJC-1295/ipamorelin blend has been studied in preclinical models for GH pulsatility and IGF-1 elevation,^[1] bone mineral content and longitudinal growth,^[4][9] periosteal bone formation rate under glucocorticoid stress,^[8] gastrointestinal motility restoration via GHS-R1a agonism,^[10] and sleep architecture via ghrelin-receptor mechanisms.^[12] No FDA-approved indication exists for either compound.

CJC-1295 amplifies the GH baseline through GHRH receptor agonism while ipamorelin triggers acute GH pulses via ghrelin-receptor binding. The two axes act supraadditively: a near-threshold GHS dose plus a maximally effective GHRH dose produced greater-than-additive GH release across five species in published research.^[13]

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — it mimics endogenous GHRH by binding pituitary GHRH receptors to amplify GH secretion. It does not administer GH directly; it stimulates the pituitary to release endogenous GH. In human studies at 60–90 µg/kg subcutaneous, mean GH rose 46% and IGF-1 rose 45% at one week.^[1]

CJC-1295 without DAC: below 30 minutes (DPP-IV-limited, analogous to native GRF(1-29), which has a half-life under 13 minutes^[16]). CJC-1295 with DAC: approximately 6–8 days (albumin-bound).^[2] Ipamorelin: approximately 2 hours in rodents — no validated human half-life data are published.^[7]

Drug Affinity Complex (DAC) modification extends CJC-1295 half-life to approximately 6–8 days by forming a covalent in vivo bond with serum albumin via the maleimidopropionamide moiety. Without DAC, CJC-1295 retains amino acid substitutions resisting DPP-IV but lacks albumin binding, producing a much shorter half-life. The DAC form produced a 4-fold increase in GH AUC over 2 hours compared with native hGRF(1-29) in rat studies.^[2]

Research protocols typically specify fasted administration. Food intake raises insulin, which triggers somatostatin release, which blunts GH pulse amplitude. In a 5-day fasting study in men, GH pulse frequency increased from 5.8 to 9.9 pulses per 24 hours and 24-hour GH concentration nearly tripled (p=0.0002), with reduced insulin establishing somatostatin suppression as the mechanism.^[11] Direct CJC-1295/ipamorelin timing trials in fasted versus fed human subjects have not been published.

Published research protocols for CJC-1295 with DAC used once-weekly or less frequent subcutaneous injection consistent with its multi-day half-life.^[1] Ipamorelin protocols in animal models specified 1–3 daily pulses.^[4][8][10] Human combination injection frequency protocols have not been published in peer-reviewed literature.

In CJC-1295 clinical study participants: injection-site reactions, transient facial flushing, peripheral edema, and mild headache. No serious adverse events attributed to CJC-1295 were reported in published healthy-subject Phase I/II-context trials. Ipamorelin Phase I data confirmed no cortisol, ACTH, FSH, LH, or prolactin elevation even at 200-fold above GH ED50.^[3]

CJC-1295 acts on the GHRH/GH/IGF-1 axis; published clinical trials did not report significant changes in testosterone, LH, or FSH compared to baseline. Ipamorelin's selectivity data in rat and swine models confirmed no FSH or LH elevation at 200-fold above GH ED50.^[3] No CJC-1295 or ipamorelin mechanism for testosterone elevation is characterized in published literature.

No published trial in healthy subjects attributed tumor development to CJC-1295 or ipamorelin. IGF-1 elevation is a theoretical oncologic concern; published CJC-1295 human trials reported no tumor-related events.^[1][6] This theoretical concern has not been resolved in controlled long-term human data.

CJC-1295 Phase II clinical trials enrolled both male and female subjects; sex-stratified adverse event analysis was not published in the primary literature. Ipamorelin animal studies have not reported sex-dependent toxicity differences. Selectivity data confirming no FSH or LH elevation^[3] holds across both sexes in published animal data.

CJC-1295 Phase II trials demonstrated statistically significant mean GH and IGF-1 increases versus baseline in healthy men.^[1] GHS synergy was confirmed across five species.^[13] Combination human efficacy data in controlled trials do not exist in peer-reviewed literature.

CJC-1295 Phase II trials showed IGF-1 elevation within 2 weeks; sustained for up to 28 days post-dose with the DAC form.^[1] Bone growth and body composition endpoints in animal studies showed measurable changes at 4–8 weeks of sustained dosing.^[4][8][9] Human combination outcome timelines have not been published.

In GH-deficient rodents, CJC-1295 produced weight normalization to normal ranges.^[5] In GH-intact mice, ipamorelin produced modest adipogenic effects — increased relative body fat and elevated food intake via GH-independent mechanisms.^[19] CJC-1295 in human trials did not produce significant weight changes at studied doses.

Sermorelin is the first 29 amino acids of GHRH (GRF(1-29)) without DPP-IV-resistant substitutions or DAC albumin-binding; its half-life is below 30 minutes. CJC-1295 (DAC form) has an approximately 6–8-day half-life.^[16][2] Published head-to-head human comparison studies are absent. Sermorelin produces acute short-lived GH pulses; CJC-1295 DAC provides sustained tonic GH baseline elevation.

MK-677 is an oral ghrelin mimetic with a 24-hour half-life and continuous GH/IGF-1 elevation; CJC-1295/ipamorelin is injectable and produces pulsatile GH release preserving circadian rhythm. MK-677 (25 mg/day) elevated mean 24-hour GH 97% ± 23% in 32 elderly subjects.^[14] Published direct comparison studies between MK-677 and CJC-1295/ipamorelin do not exist.

Secretagogues stimulate the pituitary to release endogenous GH in a pulsatile pattern preserving the IGF-1 negative feedback loop. Exogenous rhGH bypasses pituitary regulation and suppresses endogenous secretion in animal models. The preserved feedback loop under secretagogue stimulation is the proposed self-limiting mechanism — when IGF-1 rises sufficiently, somatostatin increases and pituitary GH synthesis decreases.

Neither CJC-1295 nor ipamorelin holds FDA approval for any human indication. Both appeared on FDA 503A/503B compounding restriction lists; as of December 2024 FDA PCAC briefing documents, CJC-1295 acetate forms were proposed not to be included on the 503A Bulks List. Neither compound has completed Phase III trials. For full regulatory status, see the About page.

Lyophilized peptide vials are reconstituted with bacteriostatic water in research settings. Standard reference protocols add BAC water slowly down the vial wall — not directly onto the lyophilized pellet — to avoid agitation-induced aggregation. Reconstituted solutions degrade via asparagine deamidation and should be stored at 2–8°C; degradation products may be 25–500-fold less potent than intact peptide.

No published controlled trial has formally studied this combination. The GH axis (CJC-1295/ipamorelin) and the androgen axis (TRT) are pharmacologically distinct, suggesting no direct pharmacological interaction. A published human study of GHRP-6 + GHRP-2 + sermorelin in hypogonadal men on TRT showed IGF-1 elevation without serious adverse events.^[15]

Published Phase I/II trials enrolled healthy adults aged 21–60 with normal pituitary function and no active malignancy; protocols excluded subjects with diabetes, active cancer, or pregnancy. Subject selection criteria in published trials do not constitute eligibility guidance for any non-research use.